Spotlight on Hematology

Credits: 1.00 CME
CAR T-Cell Practicums: A Discussion of Current Data and the Management of Adverse Events
Julie Vose, MD, MBA
University of Nebraska Medical Center

CAR T-Cell Practicums: A Discussion of Current Data and the Management of Adverse Events

Start

Activity Details

Free CME
1 AMA PRA Category 1 Credit(s)
Released: June 18, 2020
Expires: April 18, 2021
60 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with lymphoma/myeloma/leukemia.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Review the structure and function of CAR T-cells and the mechanism of action in patients with hematologic malignancies
  • Review clinical trial data of CAR T-cell–based therapies for the treatment of patients with lymphoma, and describe where CAR T-cell therapies might fit into the treatment landscape
  • Evaluate emerging clinical data and novel approaches to CAR T-cell therapy for patients with myeloma
  • Identify characteristics of patients with acute lymphoblastic leukemia who are appropriate for treatment with CAR T-cell therapy
  • Develop strategies to mitigate adverse events that may be encountered with the use of CAR T-cell therapy

Activity Description

This activity is designed to evaluate emerging CAR T data and discuss the challenges of managing CAR T specific adverse events to aid community clinicians who treat patients with lymphoma, myeloma, and leukemia.

Statement of Educational Need

Given the recent approval of various CAR T-cell–based therapies for the treatment of patients with hematologic malignancies, as well as the associated volume of emerging data of both currently approved and emerging CAR T-cell therapies, it is critical that oncologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage adverse events.

Faculty

Julie Vose, MD, MBA
Chief
Neumann M. and Mildred E. Harris Professorial Chair
Division of Oncology & Hematology
University of Nebraska Medical Center
Omaha, Nebraska

Disclosures
Consulting Fees: AbbVie, Acerta/AstraZeneca, BeiGene, Epizyme, Janssen/Pharmacyclic, Karyopharm, Kite Pharma, Legend Pharmaceuticals, Nordic Nanovector, Novartis, Roche, Sandoz, Vaniam Group, Verastem

Grants/Research Support: Acerta Pharma, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Incyte Corporation, Kite Pharma, Merck, Novartis, Seattle Genetics


Conflict of Interest Policy/Disclosure Statement

Faculty and Planning Committee Disclosures

As a provider accredited by ACCME, the UNMC Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

Continuing Education

The University of Nebraska Medical Center (UNMC) Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

The UNMC Center for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of the UNMC Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Materials will be available online through April 18, 2021.

Statement of Commercial Support

This activity is supported by independent educational grants from Celgene Corporation and Gilead Sciences, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

cme@bioascend.com

Activity Details

Free CME
1 AMA PRA Category 1 Credit(s)
Released: June 18, 2020
Expires: April 18, 2021
60 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with lymphoma/myeloma/leukemia.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Review the structure and function of CAR T-cells and the mechanism of action in patients with hematologic malignancies
  • Review clinical trial data of CAR T-cell–based therapies for the treatment of patients with lymphoma, and describe where CAR T-cell therapies might fit into the treatment landscape
  • Evaluate emerging clinical data and novel approaches to CAR T-cell therapy for patients with myeloma
  • Identify characteristics of patients with acute lymphoblastic leukemia who are appropriate for treatment with CAR T-cell therapy
  • Develop strategies to mitigate adverse events that may be encountered with the use of CAR T-cell therapy

Activity Description

This activity is designed to evaluate emerging CAR T data and discuss the challenges of managing CAR T specific adverse events to aid community clinicians who treat patients with lymphoma, myeloma, and leukemia.

Statement of Educational Need

Given the recent approval of various CAR T-cell–based therapies for the treatment of patients with hematologic malignancies, as well as the associated volume of emerging data of both currently approved and emerging CAR T-cell therapies, it is critical that oncologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage adverse events.

Faculty

Julie Vose, MD, MBA
Chief
Neumann M. and Mildred E. Harris Professorial Chair
Division of Oncology & Hematology
University of Nebraska Medical Center
Omaha, Nebraska

Disclosures
Consulting Fees: AbbVie, Acerta/AstraZeneca, BeiGene, Epizyme, Janssen/Pharmacyclic, Karyopharm, Kite Pharma, Legend Pharmaceuticals, Nordic Nanovector, Novartis, Roche, Sandoz, Vaniam Group, Verastem

Grants/Research Support: Acerta Pharma, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Incyte Corporation, Kite Pharma, Merck, Novartis, Seattle Genetics


Conflict of Interest Policy/Disclosure Statement

Faculty and Planning Committee Disclosures

As a provider accredited by ACCME, the UNMC Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

Continuing Education

The University of Nebraska Medical Center (UNMC) Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

The UNMC Center for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of the UNMC Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Materials will be available online through April 18, 2021.

Statement of Commercial Support

This activity is supported by independent educational grants from Celgene Corporation and Gilead Sciences, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

cme@bioascend.com

Hematology Presentations

1.00 CME / CNE / CPE
Rush University Medical Center
The Expanding Treatment Landscape of Waldenström’s Macroglobulinemia

The Expanding Treatment Landscape of Waldenström’s Macroglobulinemia

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: October 28, 2020
Expires: October 27, 2021
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Waldenström’s Macroglobulinemia.

Learning Objectives

After completing this program, participants should be able to:

  1. Summarize criteria required to accurately diagnose patients with Waldenström’s macroglobulinemia and identify those most likely to benefit from treatment
  2. Evaluate the latest clinical data on the efficacy and safety of approved and investigational therapies for patients with Waldenström’s macroglobulinemia
  3. Formulate best-practice treatment strategies for patients with Waldenström’s macroglobulinemia, taking into consideration current guidelines and expert recommendations when individualizing treatment plans

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of Waldenström’s Macroglobulinemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With the recent advances in targeted therapies for WM, the use of approved and investigational agents is anticipated to expand over the coming years. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate diagnosis and risk stratification of patients with WM and the clinical utility of agents that could significantly impact patient outcomes.

Faculty

Steven P. Treon, MD, PhD
Director, Bing Center for Waldenström's Macroglobulinemia
Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA


Conflict of Interest Policy/Disclosure Statement

Dr. Treon has consulted for Janssen Pharmaceuticals, Inc., Pharmacyclics, Inc., and BeiGene, Inc.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of 1.0 continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of 1.0 continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from Janssen Biotech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: October 28, 2020
Expires: October 27, 2021
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Waldenström’s Macroglobulinemia.

Learning Objectives

After completing this program, participants should be able to:

  1. Summarize criteria required to accurately diagnose patients with Waldenström’s macroglobulinemia and identify those most likely to benefit from treatment
  2. Evaluate the latest clinical data on the efficacy and safety of approved and investigational therapies for patients with Waldenström’s macroglobulinemia
  3. Formulate best-practice treatment strategies for patients with Waldenström’s macroglobulinemia, taking into consideration current guidelines and expert recommendations when individualizing treatment plans

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of Waldenström’s Macroglobulinemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With the recent advances in targeted therapies for WM, the use of approved and investigational agents is anticipated to expand over the coming years. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate diagnosis and risk stratification of patients with WM and the clinical utility of agents that could significantly impact patient outcomes.

Faculty

Steven P. Treon, MD, PhD
Director, Bing Center for Waldenström's Macroglobulinemia
Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA


Conflict of Interest Policy/Disclosure Statement

Dr. Treon has consulted for Janssen Pharmaceuticals, Inc., Pharmacyclics, Inc., and BeiGene, Inc.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of 1.0 continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of 1.0 continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from Janssen Biotech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

0.75 CNE
Vindico
Advances in Hemophilia A: Coordinating Care Through Effective Communication and Therapy Selection

Advances in Hemophilia A: Coordinating Care Through Effective Communication and Therapy Selection

Start

Activity Details

Free CNE
0.75 Contact Hour(s)
Released: October 8, 2020
Expires: October 7, 2021
45 minutes to complete

Accredited By

This continuing nurse education activity is provided by

Target Audience

The intended audience for this activity is registered nurses (RNs), nurse practitioners (NPs), oncology RNs, oncology NPs, hemophilia RNs, hemophilia NPs, hemophilia treatment center RNs, hemophilia treatment center NPs, and other health care professionals involved in the management of patients with hemophilia A.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Assess the latest evidence regarding treatments for patients with hemophilia A that may reduce treatment burden and enhance quality of life.
  • Identify patients with hemophilia A without factor VIII inhibitors who may benefit from newer treatment options.
  • Review strategies for educating patients with hemophilia A about their disease state and treatment options to facilitate the use of shared decision-making and improve patient satisfaction.

Activity Description

Hemophilia A is an X-linked recessive disease primarily affecting men, with an estimated 20,000 individuals in the United States having the disease. Disease severity is related to the degree to which factor VIII (FVIII) levels are reduced, with patients often requiring multiple infusions a week. Newer approaches to treating hemophilia A include extended half-life FVIII products that allow for reduced dosing, as well as emicizumab, a bispecific antibody therapy that mimics the cofactor activity of factor VIII by binding to and bridging activated factor IX and factor X. Given recent developments that include new drug approvals, expanded drug indications, and self-administration options, education is needed to keep clinicians apprised of best practices for managing hemophilia A in patients with and without inhibitors. In this CNE activity, expert faculty examine the latest evidence regarding new and emerging treatments for patients with hemophilia A and provide guidance on identifying patients with and without factor VIII inhibitors who may benefit from newer treatment options. Additionally, faculty will discuss strategies to promote shared decision-making and improve patient satisfaction.

Agenda

Introduction and Background
Regina B. Butler, RN-BC

Advances in the Management of Patients With Hemophilia A – Differentiating Options
Kerry Hansen, RN-BC

Optimizing Communication, Patient Education, and Shared Decision-Making in Patients With Hemophilia A
James E. Munn, MS, BS, BSN, RN-BC

Faculty

Activity Chair:

Regina B. Butler, RN-BC
Director, Mid-Atlantic/Region III Hemophilia Treatment Centers
Clinical Manager, Division of Hematology
Children's Hospital of Philadelphia
Philadelphia, PA

Disclosure:
Consulting Fee: Genentech, Pfizer


Faculty:

Kerry Hansen, RN, BSN
Nurse Clinician
M Health Fairview
University of Minnesota
Minneapolis, MN

Disclosure: No relevant financial relationships to disclose.


James E. Munn, MS, BS, BSN, RN-BC
Program Nurse Coordinator
University of Michigan Medical Center
Ann Arbor, MI

Disclosure:
Consulting Fee: Bayer, Sanofi Genzyme
Advisory Board: CSL Behring, Genentech, Novo Nordisk, Octapharma, Takeda


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
Disclosure:
Consulting Fee: Beckton Dickinson
Contracted Research: Beckton Dickinson

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the American Nurses Credentialing Center’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation of Credit

Vindico Medical Education will provide a maximum of 0.75 contact hour for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

This activity is approved for 0.75 contact hour(s) of continuing education by the American Association of Nurse Practitioners. Activity ID 20094522. This activity was planned in accordance with AANP Accreditation Standards and Policies.

Instructions for Receiving Credit

To participate in this CNE activity, you must read the objectives, answer the pretest questions, view the CNE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue a Contact Hours Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CNE Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CNE
0.75 Contact Hour(s)
Released: October 8, 2020
Expires: October 7, 2021
45 minutes to complete

Accredited By

This continuing nurse education activity is provided by

Target Audience

The intended audience for this activity is registered nurses (RNs), nurse practitioners (NPs), oncology RNs, oncology NPs, hemophilia RNs, hemophilia NPs, hemophilia treatment center RNs, hemophilia treatment center NPs, and other health care professionals involved in the management of patients with hemophilia A.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Assess the latest evidence regarding treatments for patients with hemophilia A that may reduce treatment burden and enhance quality of life.
  • Identify patients with hemophilia A without factor VIII inhibitors who may benefit from newer treatment options.
  • Review strategies for educating patients with hemophilia A about their disease state and treatment options to facilitate the use of shared decision-making and improve patient satisfaction.

Activity Description

Hemophilia A is an X-linked recessive disease primarily affecting men, with an estimated 20,000 individuals in the United States having the disease. Disease severity is related to the degree to which factor VIII (FVIII) levels are reduced, with patients often requiring multiple infusions a week. Newer approaches to treating hemophilia A include extended half-life FVIII products that allow for reduced dosing, as well as emicizumab, a bispecific antibody therapy that mimics the cofactor activity of factor VIII by binding to and bridging activated factor IX and factor X. Given recent developments that include new drug approvals, expanded drug indications, and self-administration options, education is needed to keep clinicians apprised of best practices for managing hemophilia A in patients with and without inhibitors. In this CNE activity, expert faculty examine the latest evidence regarding new and emerging treatments for patients with hemophilia A and provide guidance on identifying patients with and without factor VIII inhibitors who may benefit from newer treatment options. Additionally, faculty will discuss strategies to promote shared decision-making and improve patient satisfaction.

Agenda

Introduction and Background
Regina B. Butler, RN-BC

Advances in the Management of Patients With Hemophilia A – Differentiating Options
Kerry Hansen, RN-BC

Optimizing Communication, Patient Education, and Shared Decision-Making in Patients With Hemophilia A
James E. Munn, MS, BS, BSN, RN-BC

Faculty

Activity Chair:

Regina B. Butler, RN-BC
Director, Mid-Atlantic/Region III Hemophilia Treatment Centers
Clinical Manager, Division of Hematology
Children's Hospital of Philadelphia
Philadelphia, PA

Disclosure:
Consulting Fee: Genentech, Pfizer


Faculty:

Kerry Hansen, RN, BSN
Nurse Clinician
M Health Fairview
University of Minnesota
Minneapolis, MN

Disclosure: No relevant financial relationships to disclose.


James E. Munn, MS, BS, BSN, RN-BC
Program Nurse Coordinator
University of Michigan Medical Center
Ann Arbor, MI

Disclosure:
Consulting Fee: Bayer, Sanofi Genzyme
Advisory Board: CSL Behring, Genentech, Novo Nordisk, Octapharma, Takeda


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
Disclosure:
Consulting Fee: Beckton Dickinson
Contracted Research: Beckton Dickinson

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the American Nurses Credentialing Center’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation of Credit

Vindico Medical Education will provide a maximum of 0.75 contact hour for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

This activity is approved for 0.75 contact hour(s) of continuing education by the American Association of Nurse Practitioners. Activity ID 20094522. This activity was planned in accordance with AANP Accreditation Standards and Policies.

Instructions for Receiving Credit

To participate in this CNE activity, you must read the objectives, answer the pretest questions, view the CNE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue a Contact Hours Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CNE Questions?

Contact us at CME@VindicoCME.com

0.50 CME
University of Nebraska Medical Center
Expert Insights: The Expanding Role of Immunotherapy for the Treatment of Multiple Myeloma - Focus on Antibodies, Antibody-Drug Conjugates, and CAR T-Cells

Expert Insights: The Expanding Role of Immunotherapy for the Treatment of Multiple Myeloma - Focus on Antibodies, Antibody-Drug Conjugates, and CAR T-Cells

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: August 3, 2020
Expires: August 3, 2021
30 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Review unmet needs in the care of multiple myeloma (MM) and the potential role of immunotherapies such as antibodies, antibody-drug conjugates, CAR T-cells, and others
  • Evaluate clinical trial data of current and emerging immunotherapies being examined in patients with MM
  • Assess unique adverse event profiles of immunotherapies that differ from traditional therapies used for the treatment of patients with MM
  • Develop strategies to integrate immunotherapies into the MM treatment paradigm as they become available

Activity Description

Expert Insights is a summary of a virtual satellite symposium from the 2020 Clinical Oncology Meeting and will discuss current data of current and emerging immunotherapeutic-based approaches for the treatment of patients with multiple myeloma.

Statement of Educational Need

Given the recent approval of immunotherapies for the treatment of patients with multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with MM.

Agenda

  • Unmet needs
  • Monoclonal antibodies
  • BiTEs
  • Vaccines
  • ADCs
  • CAR T-cells

Faculty

Saad Z. Usmani, MD, FACP
Chief, Plasma Cell Disorders Division
Director, Clinical Research in Hematologic Malignancies
Department of Hematologic Oncology & Blood Disorders
Levine Cancer Institute
Charlotte, North Carolina

Consulting Fees: Amgen Inc., Bristol Myers Squibb, Celgene Corporation, GlaxoSmithKline, Janssen Oncology, Merck & Co., Sanofi, SkylineDX, Takeda Pharmaceutical Company

Contracted Research & Publishing: Amgen Inc., Array BioPharma, Bristol Myers Squibb, Celgene Corporation, GlaxoSmithKline, Janssen Oncology, Merck & Co., Pharmacyclics LLC, Sanofi, Seattle Genetics, SkylineDX, Takeda Pharmaceutical Company

Speaker’s Bureau: Amgen Inc., Celgene Corporation, Janssen Oncology, Sanofi, Takeda Pharmaceutical Company



Krina Patel, MD, MSc
Assistant Professor
Department of Lymphoma and Myeloma
Assistant Professor
Department of Stem Cell Transplantation
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Consulting Fees: Bristol Myers Squibb, Celgene Corporation, Cellectis, Janssen Oncology, Nektar Therapeutics, Pfizer Inc., Poseida Therapeutics, Inc., Precision BioSciences

Contracted Research & Publishing: AbbVie Inc., Bristol Myers Squibb, Celgene Corporation, Cellectis, Janssen Oncology, Nektar Therapeutics, Poseida Therapeutics, Inc., Precision BioSciences



Conflict of Interest Policy/Disclosure Statement

Faculty and Planning Committee Disclosures

As a provider accredited by ACCME, the UNMC Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

Continuing Education

The University of Nebraska Medical Center (UNMC), Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

The UNMC Center for Continuing Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of the UNMC Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Materials will be available online through August 3, 2021.

Statement of Commercial Support

This activity is supported by independent educational grants from Legend Biotech and Sanofi Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

cme@bioascend.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: August 3, 2020
Expires: August 3, 2021
30 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Review unmet needs in the care of multiple myeloma (MM) and the potential role of immunotherapies such as antibodies, antibody-drug conjugates, CAR T-cells, and others
  • Evaluate clinical trial data of current and emerging immunotherapies being examined in patients with MM
  • Assess unique adverse event profiles of immunotherapies that differ from traditional therapies used for the treatment of patients with MM
  • Develop strategies to integrate immunotherapies into the MM treatment paradigm as they become available

Activity Description

Expert Insights is a summary of a virtual satellite symposium from the 2020 Clinical Oncology Meeting and will discuss current data of current and emerging immunotherapeutic-based approaches for the treatment of patients with multiple myeloma.

Statement of Educational Need

Given the recent approval of immunotherapies for the treatment of patients with multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with MM.

Agenda

  • Unmet needs
  • Monoclonal antibodies
  • BiTEs
  • Vaccines
  • ADCs
  • CAR T-cells

Faculty

Saad Z. Usmani, MD, FACP
Chief, Plasma Cell Disorders Division
Director, Clinical Research in Hematologic Malignancies
Department of Hematologic Oncology & Blood Disorders
Levine Cancer Institute
Charlotte, North Carolina

Consulting Fees: Amgen Inc., Bristol Myers Squibb, Celgene Corporation, GlaxoSmithKline, Janssen Oncology, Merck & Co., Sanofi, SkylineDX, Takeda Pharmaceutical Company

Contracted Research & Publishing: Amgen Inc., Array BioPharma, Bristol Myers Squibb, Celgene Corporation, GlaxoSmithKline, Janssen Oncology, Merck & Co., Pharmacyclics LLC, Sanofi, Seattle Genetics, SkylineDX, Takeda Pharmaceutical Company

Speaker’s Bureau: Amgen Inc., Celgene Corporation, Janssen Oncology, Sanofi, Takeda Pharmaceutical Company



Krina Patel, MD, MSc
Assistant Professor
Department of Lymphoma and Myeloma
Assistant Professor
Department of Stem Cell Transplantation
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Consulting Fees: Bristol Myers Squibb, Celgene Corporation, Cellectis, Janssen Oncology, Nektar Therapeutics, Pfizer Inc., Poseida Therapeutics, Inc., Precision BioSciences

Contracted Research & Publishing: AbbVie Inc., Bristol Myers Squibb, Celgene Corporation, Cellectis, Janssen Oncology, Nektar Therapeutics, Poseida Therapeutics, Inc., Precision BioSciences



Conflict of Interest Policy/Disclosure Statement

Faculty and Planning Committee Disclosures

As a provider accredited by ACCME, the UNMC Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

Continuing Education

The University of Nebraska Medical Center (UNMC), Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

The UNMC Center for Continuing Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of the UNMC Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Materials will be available online through August 3, 2021.

Statement of Commercial Support

This activity is supported by independent educational grants from Legend Biotech and Sanofi Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

cme@bioascend.com

0.50 CME / CNE / CPE
Rush University Medical Center
Optimizing Treatment of B-Cell Non-Hodgkin Lymphomas in the Modern Era - Part B

Optimizing Treatment of B-Cell Non-Hodgkin Lymphomas in the Modern Era - Part B

Start

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
30 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with B-Cell Non-Hodgkin Lymphomas.

Learning Objectives

After completing this program, participants should be able to:

  • Summarize current evidence-based management strategies for treating B-cell NHLs with newer agents and combination approaches
  • Evaluate safety and efficacy data from recent clinical trials and its impact on future clinical practice
  • Formulate individualized strategies for incorporating new agents and regimens into the evolving treatment paradigms for B-cell NHLs, taking into consideration current guidelines, expert recommendations, and clinical factors

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of B-Cell Non-Hodgkin Lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for B-Cell Non-Hodgkin Lymphomas along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with B-Cell Non-Hodgkin Lymphomas, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Jonathon B. Cohen, MD, MS
Co-Director Lymphoma Program
Winship Cancer Institute
Emory University
Atlanta, GA


Conflict of Interest Policy/Disclosure Statement

Dr. Cohen has served on advisory boards for Janssen and Genentech and has done research funding for Genentech.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of 0.5 continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by educational grant from AbbVie Inc., Bayer HealthCare Pharmaceutical Inc., Celgene Corp., Janssen Biotech, Inc., and Verastem.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions about the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
30 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with B-Cell Non-Hodgkin Lymphomas.

Learning Objectives

After completing this program, participants should be able to:

  • Summarize current evidence-based management strategies for treating B-cell NHLs with newer agents and combination approaches
  • Evaluate safety and efficacy data from recent clinical trials and its impact on future clinical practice
  • Formulate individualized strategies for incorporating new agents and regimens into the evolving treatment paradigms for B-cell NHLs, taking into consideration current guidelines, expert recommendations, and clinical factors

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of B-Cell Non-Hodgkin Lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for B-Cell Non-Hodgkin Lymphomas along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with B-Cell Non-Hodgkin Lymphomas, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Jonathon B. Cohen, MD, MS
Co-Director Lymphoma Program
Winship Cancer Institute
Emory University
Atlanta, GA


Conflict of Interest Policy/Disclosure Statement

Dr. Cohen has served on advisory boards for Janssen and Genentech and has done research funding for Genentech.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of 0.5 continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by educational grant from AbbVie Inc., Bayer HealthCare Pharmaceutical Inc., Celgene Corp., Janssen Biotech, Inc., and Verastem.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions about the Activity

info@plexuscomm.com

0.50 CME / CNE / CPE
Rush University Medical Center
Optimizing Treatment of B-Cell Non-Hodgkin Lymphomas in the Modern Era - Part A

Optimizing Treatment of B-Cell Non-Hodgkin Lymphomas in the Modern Era - Part A

Start

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
30 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with B-Cell Non-Hodgkin Lymphomas.

Learning Objectives

After completing this program, participants should be able to:

  • Summarize current evidence-based management strategies for treating B-cell NHLs with newer agents and combination approaches
  • Evaluate safety and efficacy data from recent clinical trials and its impact on future clinical practice
  • Formulate individualized strategies for incorporating new agents and regimens into the evolving treatment paradigms for B-cell NHLs, taking into consideration current guidelines, expert recommendations, and clinical factors

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of B-Cell Non-Hodgkin Lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for B-Cell Non-Hodgkin Lymphomas along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with B-Cell Non-Hodgkin Lymphomas, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Jonathon B. Cohen, MD, MS
Co-Director Lymphoma Program
Winship Cancer Institute
Emory University
Atlanta, GA


Conflict of Interest Policy/Disclosure Statement

Dr. Cohen has served on advisory boards for Janssen and Genentech and has done research funding for Genentech.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of 0.5 continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by educational grant from AbbVie Inc., Bayer HealthCare Pharmaceutical Inc., Celgene Corp., Janssen Biotech, Inc., and Verastem.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions about the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
30 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with B-Cell Non-Hodgkin Lymphomas.

Learning Objectives

After completing this program, participants should be able to:

  • Summarize current evidence-based management strategies for treating B-cell NHLs with newer agents and combination approaches
  • Evaluate safety and efficacy data from recent clinical trials and its impact on future clinical practice
  • Formulate individualized strategies for incorporating new agents and regimens into the evolving treatment paradigms for B-cell NHLs, taking into consideration current guidelines, expert recommendations, and clinical factors

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of B-Cell Non-Hodgkin Lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for B-Cell Non-Hodgkin Lymphomas along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with B-Cell Non-Hodgkin Lymphomas, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Jonathon B. Cohen, MD, MS
Co-Director Lymphoma Program
Winship Cancer Institute
Emory University
Atlanta, GA


Conflict of Interest Policy/Disclosure Statement

Dr. Cohen has served on advisory boards for Janssen and Genentech and has done research funding for Genentech.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of 0.5 continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by educational grant from AbbVie Inc., Bayer HealthCare Pharmaceutical Inc., Celgene Corp., Janssen Biotech, Inc., and Verastem.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions about the Activity

info@plexuscomm.com

1.00 CME
University of Nebraska Medical Center
CAR T-Cell Practicums: A Discussion of Current Data and the Management of Adverse Events

CAR T-Cell Practicums: A Discussion of Current Data and the Management of Adverse Events

Start

Activity Details

Free CME
1 AMA PRA Category 1 Credit(s)
Released: June 18, 2020
Expires: April 18, 2021
60 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with lymphoma/myeloma/leukemia.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Review the structure and function of CAR T-cells and the mechanism of action in patients with hematologic malignancies
  • Review clinical trial data of CAR T-cell–based therapies for the treatment of patients with lymphoma, and describe where CAR T-cell therapies might fit into the treatment landscape
  • Evaluate emerging clinical data and novel approaches to CAR T-cell therapy for patients with myeloma
  • Identify characteristics of patients with acute lymphoblastic leukemia who are appropriate for treatment with CAR T-cell therapy
  • Develop strategies to mitigate adverse events that may be encountered with the use of CAR T-cell therapy

Activity Description

This activity is designed to evaluate emerging CAR T data and discuss the challenges of managing CAR T specific adverse events to aid community clinicians who treat patients with lymphoma, myeloma, and leukemia.

Statement of Educational Need

Given the recent approval of various CAR T-cell–based therapies for the treatment of patients with hematologic malignancies, as well as the associated volume of emerging data of both currently approved and emerging CAR T-cell therapies, it is critical that oncologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage adverse events.

Faculty

Julie Vose, MD, MBA
Chief
Neumann M. and Mildred E. Harris Professorial Chair
Division of Oncology & Hematology
University of Nebraska Medical Center
Omaha, Nebraska

Disclosures
Consulting Fees: AbbVie, Acerta/AstraZeneca, BeiGene, Epizyme, Janssen/Pharmacyclic, Karyopharm, Kite Pharma, Legend Pharmaceuticals, Nordic Nanovector, Novartis, Roche, Sandoz, Vaniam Group, Verastem

Grants/Research Support: Acerta Pharma, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Incyte Corporation, Kite Pharma, Merck, Novartis, Seattle Genetics


Conflict of Interest Policy/Disclosure Statement

Faculty and Planning Committee Disclosures

As a provider accredited by ACCME, the UNMC Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

Continuing Education

The University of Nebraska Medical Center (UNMC) Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

The UNMC Center for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of the UNMC Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Materials will be available online through April 18, 2021.

Statement of Commercial Support

This activity is supported by independent educational grants from Celgene Corporation and Gilead Sciences, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

cme@bioascend.com

Activity Details

Free CME
1 AMA PRA Category 1 Credit(s)
Released: June 18, 2020
Expires: April 18, 2021
60 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with lymphoma/myeloma/leukemia.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Review the structure and function of CAR T-cells and the mechanism of action in patients with hematologic malignancies
  • Review clinical trial data of CAR T-cell–based therapies for the treatment of patients with lymphoma, and describe where CAR T-cell therapies might fit into the treatment landscape
  • Evaluate emerging clinical data and novel approaches to CAR T-cell therapy for patients with myeloma
  • Identify characteristics of patients with acute lymphoblastic leukemia who are appropriate for treatment with CAR T-cell therapy
  • Develop strategies to mitigate adverse events that may be encountered with the use of CAR T-cell therapy

Activity Description

This activity is designed to evaluate emerging CAR T data and discuss the challenges of managing CAR T specific adverse events to aid community clinicians who treat patients with lymphoma, myeloma, and leukemia.

Statement of Educational Need

Given the recent approval of various CAR T-cell–based therapies for the treatment of patients with hematologic malignancies, as well as the associated volume of emerging data of both currently approved and emerging CAR T-cell therapies, it is critical that oncologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage adverse events.

Faculty

Julie Vose, MD, MBA
Chief
Neumann M. and Mildred E. Harris Professorial Chair
Division of Oncology & Hematology
University of Nebraska Medical Center
Omaha, Nebraska

Disclosures
Consulting Fees: AbbVie, Acerta/AstraZeneca, BeiGene, Epizyme, Janssen/Pharmacyclic, Karyopharm, Kite Pharma, Legend Pharmaceuticals, Nordic Nanovector, Novartis, Roche, Sandoz, Vaniam Group, Verastem

Grants/Research Support: Acerta Pharma, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Incyte Corporation, Kite Pharma, Merck, Novartis, Seattle Genetics


Conflict of Interest Policy/Disclosure Statement

Faculty and Planning Committee Disclosures

As a provider accredited by ACCME, the UNMC Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

Continuing Education

The University of Nebraska Medical Center (UNMC) Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

The UNMC Center for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of the UNMC Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Materials will be available online through April 18, 2021.

Statement of Commercial Support

This activity is supported by independent educational grants from Celgene Corporation and Gilead Sciences, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

cme@bioascend.com

1.00 CME / CNE / CPE
Rush University Medical Center
Advances in High-Risk and Relapsed/Refractory Acute Myeloid Leukemia

Advances in High-Risk and Relapsed/Refractory Acute Myeloid Leukemia

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
1 hour to complete

Accredited By

Rush University Medical Center

Co-provided By

Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with acute myeloid leukemia.

Learning Objectives

After completing this program, participants should be able to:

  • Outline the recently modified recommendations for the risk stratification and classification of patients with AML and how this classification impacts treatment decisions
  • Incorporate recently approved therapies into clinical treatment of patients with high-risk or relapsed/refractory AML
  • Discuss the novel investigational agents under development and review the considerations for their potential clinical use in patients with AML

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of acute myeloid leukemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for acute myeloid leukemia along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with acute myeloid leukemia, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Mark Levis, MD, PhD
Director, Adult Leukemia Service
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Conflict of Interest Policy/Disclosure Statement

Dr. Levis receives research funding from Astellas Global Pharma, FujiFilm, and Novartis. Dr. Levis provides consulting/honoraria to Agios, Daiichi-Sankyo, Amgen, Menarini, and Novartis.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie, Agios, and Astellas.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
1 hour to complete

Accredited By

Rush University Medical Center

Co-provided By

Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with acute myeloid leukemia.

Learning Objectives

After completing this program, participants should be able to:

  • Outline the recently modified recommendations for the risk stratification and classification of patients with AML and how this classification impacts treatment decisions
  • Incorporate recently approved therapies into clinical treatment of patients with high-risk or relapsed/refractory AML
  • Discuss the novel investigational agents under development and review the considerations for their potential clinical use in patients with AML

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of acute myeloid leukemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for acute myeloid leukemia along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with acute myeloid leukemia, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Mark Levis, MD, PhD
Director, Adult Leukemia Service
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Conflict of Interest Policy/Disclosure Statement

Dr. Levis receives research funding from Astellas Global Pharma, FujiFilm, and Novartis. Dr. Levis provides consulting/honoraria to Agios, Daiichi-Sankyo, Amgen, Menarini, and Novartis.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie, Agios, and Astellas.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

1.00 CME / CNE / CPE
Rush University Medical Center
Emerging Strategies for the Management of Chronic Lymphocytic Leukemia

Emerging Strategies for the Management of Chronic Lymphocytic Leukemia

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
1 hour to complete

Accredited By

Rush University Medical Center

Co-provided by

Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with chronic lymphocytic leukemia.

Learning Objectives

After completing this program, participants should be able to:

  • Apply the latest data to risk stratify and optimize treatment plans for patients with CLL based on prognostic and predictive markers
  • Differentiate between first-line and relapsed/refractory treatment approaches for the treatment of CLL using the latest evidence-based guidelines
  • Explain the emerging clinical data and ongoing trials on novel agents and therapeutic strategies that have the potential to improve patient outcomes for patients with CLL
  • Summarize evidence-based management strategies that can be used to identify and treat acute and long-term complications associated with CLL treatment

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of chronic lymphocytic leukemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for chronic lymphocytic leukemia along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with chronic lymphocytic leukemia, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Joao Ascensao, MD
Washington DC Veterans Affairs Medical Center
Washington, DC


Conflict of Interest Policy/Disclosure Statement

Dr. Ascensao has no conflict of interest with any commercial interest(s) whose products or services may be mentioned in this activity.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from AstraZeneca and Janssen Biotech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions about the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
1 hour to complete

Accredited By

Rush University Medical Center

Co-provided by

Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with chronic lymphocytic leukemia.

Learning Objectives

After completing this program, participants should be able to:

  • Apply the latest data to risk stratify and optimize treatment plans for patients with CLL based on prognostic and predictive markers
  • Differentiate between first-line and relapsed/refractory treatment approaches for the treatment of CLL using the latest evidence-based guidelines
  • Explain the emerging clinical data and ongoing trials on novel agents and therapeutic strategies that have the potential to improve patient outcomes for patients with CLL
  • Summarize evidence-based management strategies that can be used to identify and treat acute and long-term complications associated with CLL treatment

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of chronic lymphocytic leukemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for chronic lymphocytic leukemia along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with chronic lymphocytic leukemia, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Joao Ascensao, MD
Washington DC Veterans Affairs Medical Center
Washington, DC


Conflict of Interest Policy/Disclosure Statement

Dr. Ascensao has no conflict of interest with any commercial interest(s) whose products or services may be mentioned in this activity.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from AstraZeneca and Janssen Biotech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions about the Activity

info@plexuscomm.com

1.00 CME / CNE / CPE
Rush University Medical Center
Current Trends in Multiple Myeloma: Customizing Treatment Strategies and Optimizing Outcomes

Current Trends in Multiple Myeloma: Customizing Treatment Strategies and Optimizing Outcomes

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1 Contact Hour(s)
1 hour to complete

Accredited By

Rush University Medical Center

Co-provided by


Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with multiple myeloma.

Learning Objectives

After completing this program, participants should be able to:

  • Formulate individualized, evidence-based treatment plans for multiple myeloma patients in the VHA, DoD and MHS settings, by applying current standards of care and appropriately sequencing new agents and combinations while considering expert recommendations, disease and patient characteristics and patient needs/preferences
  • Evaluate the latest clinical trial data including the evolution of new classes of therapeutics and how to safely and effectively integrate them into care across the disease spectrum of multiple myeloma
  • Describe the risks and benefits of current, evolving, and future treatment approaches for multiple myeloma to optimize patient outcomes

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of multiple myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for multiple myeloma along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with multiple myeloma, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Joshua Richter, MD

Mount Sinai Hospital
New York, NY


Conflict of Interest Policy/Disclosure Statement

Dr. Richter is a consultant to Karyopharm, BMS/Pfizer, Celgene, and Janssen. Dr. Richter is also a Member, Speakers Bureau, for Janssen and Celgene.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Janssen Biotech, Inc. and Celgene.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions about the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1 Contact Hour(s)
1 hour to complete

Accredited By

Rush University Medical Center

Co-provided by


Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with multiple myeloma.

Learning Objectives

After completing this program, participants should be able to:

  • Formulate individualized, evidence-based treatment plans for multiple myeloma patients in the VHA, DoD and MHS settings, by applying current standards of care and appropriately sequencing new agents and combinations while considering expert recommendations, disease and patient characteristics and patient needs/preferences
  • Evaluate the latest clinical trial data including the evolution of new classes of therapeutics and how to safely and effectively integrate them into care across the disease spectrum of multiple myeloma
  • Describe the risks and benefits of current, evolving, and future treatment approaches for multiple myeloma to optimize patient outcomes

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of multiple myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for multiple myeloma along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with multiple myeloma, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Joshua Richter, MD

Mount Sinai Hospital
New York, NY


Conflict of Interest Policy/Disclosure Statement

Dr. Richter is a consultant to Karyopharm, BMS/Pfizer, Celgene, and Janssen. Dr. Richter is also a Member, Speakers Bureau, for Janssen and Celgene.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Janssen Biotech, Inc. and Celgene.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions about the Activity

info@plexuscomm.com

1.00 CME / CNE / CPE
Rush University Medical Center
Expert Guidance on the Latest Developments, Treatment Strategies, and Emerging Clinical Data in the Management of Multiple Myeloma

Expert Guidance on the Latest Developments, Treatment Strategies, and Emerging Clinical Data in the Management of Multiple Myeloma

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
1 hour to complete

Accredited by

Rush University Medical Center

Co-provided by

Target Audience 

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with multiple myeloma.

Learning Objectives

After completing this program, participants should be able to:

  • Apply evidence-based best clinical practices for treating multiple myeloma patients throughout the disease continuum
  • Summarize the latest data from finalized and ongoing clinical trials, including the evaluation of new classes of therapeutics and review the contexts for their potential clinical use in patients with multiple myeloma
  • Determine the risks and benefits of current, evolving, and future treatment approaches for multiple myeloma to optimize patient outcomes

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of multiple myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for multiple myeloma along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with multiple myeloma, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Carol Ann Huff, MD
Carol Ann Huff, MD
Associate Professor of Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD


Conflict of Interest Policy/Disclosure Statement

Dr. Huff has disclosed having financial arrangements or affiliations with the following commercial interest(s) whose products or services may be mentioned in this activity.

Consultant: Johnson and Johnson, Sanofi, Karyopharm.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s). Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Amgen, Celgene, and Sanofi Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions about the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
1 hour to complete

Accredited by

Rush University Medical Center

Co-provided by

Target Audience 

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with multiple myeloma.

Learning Objectives

After completing this program, participants should be able to:

  • Apply evidence-based best clinical practices for treating multiple myeloma patients throughout the disease continuum
  • Summarize the latest data from finalized and ongoing clinical trials, including the evaluation of new classes of therapeutics and review the contexts for their potential clinical use in patients with multiple myeloma
  • Determine the risks and benefits of current, evolving, and future treatment approaches for multiple myeloma to optimize patient outcomes

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of multiple myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for multiple myeloma along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with multiple myeloma, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Carol Ann Huff, MD
Carol Ann Huff, MD
Associate Professor of Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD


Conflict of Interest Policy/Disclosure Statement

Dr. Huff has disclosed having financial arrangements or affiliations with the following commercial interest(s) whose products or services may be mentioned in this activity.

Consultant: Johnson and Johnson, Sanofi, Karyopharm.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s). Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Amgen, Celgene, and Sanofi Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions about the Activity

info@plexuscomm.com